Trastuzumab biosimilar (Zhejiang Hisun Pharmaceutical)

曲妥珠单抗生物类似药（浙江海正药业）

Report date: 2023/03/07 11:15:42

Base Information

Drug NameTrastuzumab biosimilar (Zhejiang Hisun Pharmaceutical)
Drug Alias Name曲妥珠单抗生物仿制药（浙江海正药业）安瑞泽HS-022
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsStomach NeoplasmsBreast Neoplasms
Global Approved IndicationsStomach NeoplasmsBreast Neoplasms
Approved Indications in ChinaStomach NeoplasmsBreast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2023/02/28
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhejiang Hisun Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHisun Biopharmaceutical Co Ltd
Inactive CompaniesHarbin Medical University Cancer HospitalHenan Provincial Cancer HospitalLiaoning Cancer Hospital (Liaoning Cancer Institute) +[7] 
Active IndicationsStomach NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeL01XC03
Related LinksN/A